Home Page

NEW YORK, March 27, 2015 /PRNewswire/ -- BioCorRx, Inc. (BICX) operating in Santa Ana, California is a healthcare solutions organization, which focuses solely on addiction treatment; the market for which is estimated at $22 billion in the U.S. alone. The Company created a unique treatment program which includes the use of FDA-approved Naltrexone in a specially compounded form for outpatient surgical implantation. The Company has exclusive rights (excluding Australia and New Zealand) to the specially formulated Naltrexone implant. The treatment program also includes an outpatient coaching regimen in which patients receive psycho-social therapy and support for their alcohol or substance abuse addictions.

The Company has strategic partnerships in the pipeline in which it hopes to increase its assets. They recently issued a letter of understanding to acquire Trinity RX Solutions (owner of the specific Naltrexone implant formula used by the Company) and all of its formulas. The Company has exclusive perpetual rights to the implant, however they are in the process of obtaining ownership of the formula outright. Through licensing of its Start Fresh Program, the Company has also begun to plan the introduction of the program to wellness centers across America. A pilot program is planned to be introduced to five wellness centers, and upon successful completion, the Start Fresh Program will be made available to Physicians Business Solutions' network of approximately 1000 medical centers nationwide via a definitive agreement recently executed with Myriad Medical Marketing.

On March 27, 2015 there was a press release issued by Small Cap IR that was not authorized by BioCorRx Inc. which contained some inaccurate disclosures which have been corrected within this press release. Shareholders and investors should not rely on anything in this earlier press release and should instead carefully review the accurate disclosures set forth above.

SOURCE Small Cap IR